| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |